Company / SG&A Expense
Protara Therapeutics, Inc. SG&A Expense History
FY2014-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$4.1M
FY2016
5-year range
$2.1M / $4.1M
FY2014-FY2016
Trend
+30.9%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Increased from $2M to $4M over the past 2 years.
Based on SEC 10-K filings.
$4M in FY2016.
Increased from $2M to $4M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2016, sg&a expense increased 30.9% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.74 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $4.1M | +30.9% |
| FY2015 | $3.1M | +49.7% |
| FY2014 | $2.1M | - |
As of FY2016 · SEC 10-K · Updated Jun 28, 2026